Brought to you by 
Elixir Medical gets rights to Novartis' Myolimus
07 Nov 2008
Executive Summary
Novartis has granted Elixir Medical (next-generation drug-eluting stent systems) co-exclusive global rights to use Myolimus for Elixir's vascular and other site-specific drug delivery applications. Elixir also gets an exclusive worldwide license to use the drug in fully biodegradable stents.
Deal Industry
- Biotechnology
- Medical Devices
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
-
Medical Devices
- Biomaterials
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Elixir Medical gets rights to Novartis' Myolimus
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice